Aurora Therapeutics

About Aurora Therapeutics

Aurora Therapeutics is pioneering the first truly scalable platform for personalized gene editing, transforming isolated medical breakthroughs into a sustainable framework capable of treating millions of patients with rare genetic diseases. Founded on the vision of CRISPR pioneers Dr. Jennifer Doudna and Dr. Fyodor Urnov, Aurora’s mission is to ensure that no genetic mutation is left behind simply because it is too rare to attract traditional pharmaceutical development.

Rare genetic diseases are collectively widespread, impacting hundreds of millions of people worldwide. However, because these diseases are often driven by dozens or even thousands of distinct, mutation-specific variations within a single gene, the traditional blockbuster drug model fails them. Developing bespoke, one-off therapies for individual mutations has historically been an operationally complex, economically unviable, and isolated "heroic effort." As a result, the vast majority of rare-disease patients are left waiting without a cure.

Aurora is rewriting the rulebook of genomic medicine by shifting from a product-by-product approach to an industrialized, highly parallelized development engine. By leveraging the intrinsic programmability of modern CRISPR systems, we design state-of-the-art therapies capable of permanently correcting disease-causing mutations with a single course of treatment.

Aurora’s initial therapeutic focus centers on inborn errors of metabolism—a vast class of single-gene genetic disorders. Our flagship program targets Phenylketonuria (PKU), a severe metabolic disorder caused by a wide range of mutations in the PAH gene. Left unmanaged, PKU leads to toxic phenylalanine accumulation in the blood, causing lifelong cognitive and neurological impairments. Aurora is designing therapeutics intended to address multiple PKU-causing mutations from the outset, paving the way to expand this umbrella approach to a broader universe of rare genetic diseases.

Backed by a $16 million seed financing led by Menlo Ventures and steered by an executive team of veteran biotechnology and rare-disease experts, Aurora Therapeutics is closing the gap between scientific possibility and patient accessibility. We are not just engineering cures; we are reinventing the route to patients at a population scale.